Bristol-Myers Squibb Debt to Equity Ratio 2006-2018 | BMY

Current and historical debt to equity ratio values for Bristol-Myers Squibb (BMY) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Bristol-Myers Squibb debt/equity for the three months ending September 30, 2018 was 0.41.
Bristol-Myers Squibb Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2018-09-30 $5.69B $13.75B 0.41
2018-06-30 $5.67B $12.42B 0.46
2018-03-31 $5.78B $12.91B 0.45
2017-12-31 $6.98B $11.85B 0.59
2017-09-30 $6.98B $14.91B 0.47
2017-06-30 $6.91B $14.82B 0.47
2017-03-31 $7.24B $14.54B 0.50
2016-12-31 $5.72B $16.35B 0.35
2016-09-30 $5.84B $15.78B 0.37
2016-06-30 $6.58B $15.08B 0.44
2016-03-31 $6.59B $14.55B 0.45
2015-12-31 $6.55B $14.42B 0.45
2015-09-30 $6.63B $15.27B 0.43
2015-06-30 $6.62B $15.29B 0.43
2015-03-31 $7.13B $15.69B 0.45
2014-12-31 $7.24B $14.98B 0.48
2014-09-30 $7.27B $15.20B 0.48
2014-06-30 $7.37B $15.38B 0.48
2014-03-31 $7.37B $15.53B 0.47
2013-12-31 $7.98B $15.24B 0.52
2013-09-30 $6.53B $14.71B 0.44
2013-06-30 $6.44B $14.37B 0.45
2013-03-31 $6.52B $13.70B 0.48
2012-12-31 $6.57B $13.64B 0.48
2012-09-30 $6.61B $13.90B 0.48
2012-06-30 $5.21B $15.81B 0.33
2012-03-31 $5.27B $16.25B 0.32
2011-12-31 $5.38B $15.87B 0.34
2011-09-30 $5.44B $16.44B 0.33
2011-06-30 $5.33B $16.15B 0.33
2011-03-31 $5.28B $15.90B 0.33
2010-12-31 $5.33B $15.64B 0.34
2010-09-30 $6.48B $15.86B 0.41
2010-06-30 $6.25B $15.57B 0.40
2010-03-31 $6.08B $15.23B 0.40
2009-12-31 $6.13B $14.79B 0.42
2009-09-30 $6.31B $14.37B 0.44
2009-06-30 $6.24B $13.94B 0.45
2009-03-31 $6.49B $13.13B 0.49
2008-12-31 $6.59B $12.21B 0.54
2008-09-30 $6.12B $12.94B 0.47
2008-06-30 $6.02B $10.78B 0.56
2008-03-31 $4.66B $10.56B 0.44
2007-12-31 $4.38B $10.56B 0.42
2007-09-30 $4.25B $11.15B 0.38
2007-06-30 $6.98B $10.76B 0.65
2007-03-31 $7.13B $10.26B 0.70
2006-12-31 $7.25B $9.99B 0.73
2006-09-30 $7.84B $11.59B 0.68
2006-06-30 $8.24B $11.71B 0.70
2006-03-31 $8.28B $11.56B 0.72
2005-12-31 $8.36B $11.21B 0.75
2005-09-30 $5.90B $11.27B 0.52
2005-06-30 $6.01B $10.80B 0.56
2005-03-31 $8.33B $10.38B 0.80
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $85.837B $20.776B
Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Their employees around the world work together for patients - it drives everything they do. They are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through their R&D organization, they have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate their work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $388.162B 18.20
Pfizer (PFE) United States $259.069B 14.60
Novartis AG (NVS) Switzerland $204.655B 17.49
Merck (MRK) United States $201.163B 17.43
AbbVie (ABBV) United States $132.702B 11.78
Eli Lilly (LLY) United States $119.057B 20.93
Sanofi (SNY) France $112.613B 13.94
Novo Nordisk (NVO) Denmark $107.980B 17.54
AstraZeneca (AZN) United Kingdom $105.090B 13.05
GlaxoSmithKline (GSK) United Kingdom $102.669B 13.80